



BMT CTN 0502

Allogeneic PBSCT with Reduced Intensity Conditioning for AML in the Elderly


Objective

- Determine if matched sibling or unrelated donor using non-myeloablative regimen results in improved 2 year DFS

Eligibility

- AML (except FAB M3)
- CR1:
 - Sustained ≥ 30 days
 - After ≤ 2 cycles of induction therapy
 - No $>$ than 2 cycles consolidation
- 6/6 HLA matched sibling **OR** 10/10 HLA matched unrelated donor
- Age ≥ 60 and < 75 years

TREATMENT SCHEMA



To view entire protocol, go to <http://www.bmtctn.net>
or the PDQ website at <http://cancer.gov/clinicaltrials/BMTCTN-0502>

This is a Phase II multi-center trial cosponsored by CALGB and BMT CTN
which are funded by NHLBI and NCI.